论文部分内容阅读
度拉鲁肽单药治疗T2DM优于格理美脲一项为期26周的Ⅲ期随机双盲平行试验,比较了每周一次度拉鲁肽(DU)(长效GLP-1受体激动剂)单药疗法与恪列美脲在亚洲2型糖尿病患者中的疗效和安全性。研究对象为807名亚洲地区已停用降高血糖药物(OAM)或OAM初治2型糖尿病患者,按1:1:1比例,将患者随机分为DU 1.5mg/周治疗组、DU 0.75mg/周治疗组以及格列美脲(1~3mg/d)治疗组。26周后结果显示,DU 1.5mg和0.75mg治疗组疗效优于格列美脲。与格列美脲比较,DU 1.5mg和
DuraLuride monotherapy for T2DM is superior to glimepiride A 26-week, phase III, randomized, double-blind, parallel trial comparing once-weekly degranulation (long-acting GLP-1 receptor agonist) Monotherapy and chlamydia in type 2 diabetes in Asia, the efficacy and safety. The study population of 807 patients with OAM or OAM naïve type 2 diabetes was discontinued in Asia. The patients were randomly assigned to treatment with DU 1.5 mg / week and DU 0.75 mg at a 1: 1: 1 ratio / Week treatment group and glimepiride (1 ~ 3mg / d) treatment group. After 26 weeks, the results showed that DU 1.5mg and 0.75mg treatment group is superior to glimepiride. Compared with glimepiride, DU 1.5mg and